Researcher

Yan Yang

Hunan University

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 14, 2026 · JOURNAL ARTICLE

Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)

Diabetes Therapy

This is a design and baseline characteristics report of an ongoing Phase 3 trial with no efficacy or safety results reported; it describes the study protocol and enrolled population but cannot yet support clinical claims.

PreliminaryPharmacology and Obesity Treatment Isabel M. Kloer Liming Chen

Reported

Sample size306

Mean age at baseline36.9 years

Mean body weight at baseline93.9 kg

AUG 13, 2026 · JOURNAL ARTICLE

Bioactive PdPt nanosheets for hypoxia modulation-enhanced radiotherapy

Nano Today

Preclinical in vivo study of a novel nanoparticle platform demonstrating mechanistic effects on tumor hypoxia and radiosensitivity in animal models, without clinical trial data or direct comparison to standard therapy.

Hypothesis-GeneratingFeng Zhao Yue You Kaijie Feng

Study details

DesignPreclinical in vivo study

InterventionPdPt nanosheets modified with bovine serum…